Frontlight ResearchEarly access
Active, not recruitingPhase 2
Early Intervention for Premyopic Children
Key facts
- Who runs it
- National Yang Ming Chiao Tung University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 240 people, planned
- Started
- 6 Oct 2024
- Ended
- Jul 2026
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- MiyoSmart Spectacles
- 0.01% atropine
- Record updated
- 12 June 2025
Who can take part
- Age
- 5 years to 6 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age at enrollment: 5-6 years old (the senior grade of kindergarten)
- Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): < +1.00 D and > -0.50 D
- Astigmatism: 1.0 D or less in both eyes
- Anisometropia: 1.50 D or less
- Monocular uncorrected visual acuity: 6/7.5 or better in both eyes
- Either of the parents with moderate myopia
- Acceptance of random group allocation
- Submission of complete informed consent
Who cannot take part
- Previous treatment of atropine or other myopia control intervention
- Strabismus or any ocular motility disorder
- Any ophthalmic and systemic disorders that might affect visual functions or refractive development
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this research project is to add evidence of pharmacological (0.01% atropine) and optical (Defocus Integrated Multiple Segments spectacle lenses) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.
The 3 groups in the trial
- DIMS lensTreatment being tested
DIMS spectacle lenses. Daily wear for 1.5 years.
Treatment: MiyoSmart Spectacles
- 0.01% AtropineTreatment being tested
0.01% Atropine. One drop per eye, per day, for 1.5 years.
- Usual careNo study treatment, for comparison
Usual care including promoting outdoor time
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Intervention for Premyopic Children: A Comparison Study of Defocus Integrated Multiple Segments Spectacle Lenses, 0.01% Atropine and Usual Care for Myopia Prevention
- Publications
- Record updated
- 12 June 2025